Literature DB >> 19018860

Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.

Silvia Mangiacavalli, Gianmatteo Pica, Marzia Varettoni, Mario Lazzarino, Alessandro Corso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19018860     DOI： 10.1111/j.1600-0609.2008.01184.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  3 in total

1.  Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

Authors:  K Martin Kortuem; Kaitlyn Zidich; Steven R Schuster; Meaghan L Khan; Victor H Jimenez-Zepeda; Joseph R Mikhael; Rafael Fonseca; A Keith Stewart
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-28

2.  Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Authors:  Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Luigi Aloj; Gaetana Capobianco; Cristina Becchimanzi; Emanuela Morelli; Francesco Volzone; Gianpaolo Marcacci; Filippo Russo; Rosaria De Filippi; Secondo Lastoria; Antonio Pinto
Journal:  Eur J Haematol       Date:  2011-07-31       Impact factor: 2.997

3.  Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Authors:  Silvia Mangiacavalli; Lara Pochintesta; Cristiana Pascutto; Federica Cocito; Alessandra Pompa; Mario Cazzola; Alessandro Corso
Journal:  Am J Hematol       Date:  2012-12-08       Impact factor: 10.047
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.